Published in Mol Cancer Ther on March 01, 2007
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (2013) 2.00
Glutamate release by primary brain tumors induces epileptic activity. Nat Med (2011) 2.00
Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res (2013) 1.84
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res (2009) 1.79
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol (2010) 1.65
Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol (2011) 1.63
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res (2008) 1.51
Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One (2010) 1.44
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell (2016) 1.43
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell (2016) 1.43
Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp (2010) 1.39
The interface between glial progenitors and gliomas. Acta Neuropathol (2008) 1.33
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys (2009) 1.32
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol (2012) 1.32
EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol (2010) 1.29
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther (2009) 1.28
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol (2008) 1.28
A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol (2009) 1.26
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2010) 1.22
Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics (2009) 1.22
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets (2012) 1.21
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res (2008) 1.21
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther (2009) 1.18
Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol (2011) 1.16
Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol (2013) 1.15
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A (2012) 1.15
Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage (2011) 1.13
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov (2013) 1.07
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene (2011) 1.07
Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res (2010) 1.06
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One (2010) 1.05
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol (2014) 1.05
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A (2011) 1.01
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res (2008) 1.01
The Pyk2 FERM domain as a target to inhibit glioma migration. Mol Cancer Ther (2009) 0.98
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res (2009) 0.98
Targeted therapies for malignant glioma: progress and potential. BioDrugs (2009) 0.97
Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One (2013) 0.95
Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther (2009) 0.95
Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med (2011) 0.94
An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem (2010) 0.94
MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res (2012) 0.93
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res (2013) 0.91
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro Oncol (2010) 0.91
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell (2015) 0.91
New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res (2011) 0.90
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS One (2012) 0.89
Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells. J Transl Med (2014) 0.89
A proinvasive role for the Ca(2+) -activated K(+) channel KCa3.1 in malignant glioma. Glia (2014) 0.89
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med (2010) 0.88
Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol (2012) 0.88
Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. Sci Signal (2014) 0.88
Glutamate and tumor-associated epilepsy: glial cell dysfunction in the peritumoral environment. Neurochem Int (2013) 0.88
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther (2010) 0.88
Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci (2015) 0.87
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition. Clin Cancer Res (2013) 0.86
Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics. OMICS (2012) 0.86
TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance. Mol Cancer Res (2013) 0.84
Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene (2014) 0.83
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol (2015) 0.83
Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol (2011) 0.83
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. J Natl Cancer Inst (2015) 0.83
Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. Brain Pathol (2011) 0.82
Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors. Neurosurg Rev (2010) 0.81
Contemporary murine models in preclinical astrocytoma drug development. Neuro Oncol (2014) 0.81
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol (2016) 0.80
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs (2011) 0.78
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther (2014) 0.78
Patient-Derived Xenografts as a Model System for Radiation Research. Semin Radiat Oncol (2015) 0.78
Large-scale assessment of the gliomasphere model system. Neuro Oncol (2016) 0.77
Src family kinases differentially influence glioma growth and motility. Mol Oncol (2015) 0.77
Incorporating molecular tools into early-stage clinical trials. PLoS Med (2008) 0.76
Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma. Mol Ther (2015) 0.76
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer (2015) 0.76
Shared Intelligence: A Patient-Derived, Deeply Characterized Glioblastoma Cell Line Resource. EBioMedicine (2015) 0.75
Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma. Mol Cancer Ther (2016) 0.75
Network Modeling Identifies Patient-specific Pathways in Glioblastoma. Sci Rep (2016) 0.75
Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature. Neuro Oncol (2015) 0.75
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res (2015) 0.75
Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity. PLoS One (2013) 0.75
Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway. J Neurooncol (2015) 0.75
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget (2017) 0.75
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol (2007) 4.68
Incidence of treated cardiac arrest in hospitalized patients in the United States. Crit Care Med (2011) 4.43
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol (2010) 4.18
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol (2005) 4.10
Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell (2012) 4.03
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell (2003) 3.90
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature (2010) 3.84
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res (2006) 3.83
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA (2013) 3.30
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
Influenza-associated hospitalization in a subtropical city. PLoS Med (2006) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 3.05
Retracted Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem (2002) 2.97
Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature (2004) 2.90
The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell (2010) 2.89
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev (2013) 2.86
Coronary revascularization trends in the United States, 2001-2008. JAMA (2011) 2.81
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42
Third- and fourth-degree perineal lacerations: defining high-risk clinical clusters. Am J Obstet Gynecol (2011) 2.42
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol (2012) 2.35
Commuting and health in Cambridge: a study of a 'natural experiment' in the provision of new transport infrastructure. BMC Public Health (2010) 2.31
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res (2007) 2.15
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
Robust segmentation of overlapping cells in histopathology specimens using parallel seed detection and repulsive level set. IEEE Trans Biomed Eng (2011) 2.08
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. Can J Cardiol (2012) 2.06
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (2013) 2.00
Wrong side dilated pupil. Neurology (2014) 1.98
Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol (2010) 1.97
Framing Financial Incentives to Increase Physical Activity Among Overweight and Obese Adults: A Randomized, Controlled Trial. Ann Intern Med (2016) 1.96
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood (2006) 1.95
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94
Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg (2006) 1.93
Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem (2003) 1.90
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther (2004) 1.90
Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol (2010) 1.90
DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale. Nucleic Acids Res (2013) 1.86
Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol (2004) 1.85
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Coordinated redistribution of leukocyte LFA-1 and endothelial cell ICAM-1 accompany neutrophil transmigration. J Exp Med (2004) 1.85
Pleiotropic role for MYCN in medulloblastoma. Genes Dev (2010) 1.84
Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis (2011) 1.81
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res (2010) 1.81
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res (2009) 1.79
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet (2011) 1.77
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg (2007) 1.77
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res (2002) 1.76
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet (2012) 1.73
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
Structure of transmembrane pore induced by Bax-derived peptide: evidence for lipidic pores. Proc Natl Acad Sci U S A (2008) 1.70
Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology (2011) 1.70
Histone H3 as a novel substrate for MAP kinase phosphatase-1. Am J Physiol Cell Physiol (2008) 1.68
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging (2011) 1.65
Effect of continuous compressions and 30:2 cardiopulmonary resuscitation on global ventilation/perfusion values during resuscitation in a porcine model. Crit Care Med (2010) 1.65
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65